UPEXI, INC. Faces Delisting Concerns
Ticker: UPXI · Form: 8-K · Filed: Nov 22, 2024 · CIK: 1775194
| Field | Detail |
|---|---|
| Company | Upexi, Inc. (UPXI) |
| Form Type | 8-K |
| Filed Date | Nov 22, 2024 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-rules, regulatory
TL;DR
UPEXI might get delisted, stock could be toast.
AI Summary
UPEXI, INC. filed an 8-K on November 20, 2024, reporting a notice of delisting or failure to satisfy continued listing rules. The company, formerly known as GROVE, INC., is incorporated in Nevada and operates in the medicinal chemicals & botanical products sector.
Why It Matters
This filing indicates potential issues with UPEXI, INC.'s ability to remain listed on an exchange, which could significantly impact its stock liquidity and investor confidence.
Risk Assessment
Risk Level: high — A notice of delisting directly threatens the company's public trading status and can lead to severe liquidity issues and investor panic.
Key Players & Entities
- UPEXI, INC. (company) — Registrant
- GROVE, INC. (company) — Former company name
- November 20, 2024 (date) — Date of earliest event reported
- Nevada (jurisdiction) — State of incorporation
- MEDICINAL CHEMICALS & BOTANICAL PRODUCTS (industry) — Standard Industrial Classification
FAQ
What specific listing rule or standard has UPEXI, INC. failed to satisfy?
The filing does not specify the exact rule or standard that UPEXI, INC. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on November 20, 2024.
What was UPEXI, INC.'s former company name?
UPEXI, INC.'s former company name was GROVE, INC.
In which U.S. state is UPEXI, INC. incorporated?
UPEXI, INC. is incorporated in Nevada.
What is the Standard Industrial Classification code and description for UPEXI, INC.?
The Standard Industrial Classification code for UPEXI, INC. is 2833, which corresponds to MEDICINAL CHEMICALS & BOTANICAL PRODUCTS.
Filing Stats: 1,005 words · 4 min read · ~3 pages · Grade level 12.8 · Accepted 2024-11-22 09:28:01
Key Financial Figures
- $0.001 — ch registered Common Stock, par value $0.001 UPXI NASDAQ Indicate by check mar
Filing Documents
- upxi_8k.htm (8-K) — 27KB
- upxi_ex991.htm (EX-99.1) — 6KB
- upxi_ex991img2.jpg (GRAPHIC) — 4KB
- 0001477932-24-007566.txt ( ) — 167KB
- upxi-20241120.xsd (EX-101.SCH) — 6KB
- upxi-20241120_lab.xml (EX-101.LAB) — 15KB
- upxi-20241120_cal.xml (EX-101.CAL) — 1KB
- upxi-20241120_pre.xml (EX-101.PRE) — 9KB
- upxi-20241120_def.xml (EX-101.DEF) — 2KB
- upxi_8k_htm.xml (XML) — 4KB
01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On November 20, 2024, Upexi, Inc. (the " Company ") received a notice (the " Notice ") from The Nasdaq Stock Market LLC (" Nasdaq ") indicating that, as a result of not having timely filed the Company's Quarterly Report on Form 10-Q for the period ended September 30, 2024, and because the Company remains delinquent in filing its Annual Report on Form 10-K for the year ended June 30, 2024 (the " Initial Delinquent Filing "), the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic reports with the SEC. Pursuant to the Nasdaq Listing Rules, the Company has until December 20, 2024 to submit a plan to regain compliance. If the plan is accepted, an extension may be granted of up to 180 calendar days from the due date of the Initial Delinquent Filing, or April 14, 2025, to regain compliance. The Notice has no immediate effect on the listing or trading of the Company's common stock. The Company intends to file the Form 10-Q and the Initial Delinquent Filing on or before December 20, 2024.
01 Other Events
Item 8.01 Other Events. On November 22, 2024, the Company issued a press release announcing receipt of the Notice from Nasdaq, a copy of which is attached as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in Item 8.01, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the " Exchange Act "), nor shall it be deemed incorporated by reference in any of the Company's filings under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date hereof, except as shall be expressly set forth by specific reference to this Report in such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits (d) Exhibits 99.1 Press Release dated November 22, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)
Forward-Looking Statements
Forward-Looking Statements Certain statements and information included in this current report constitute "forward-looking statements" within the meaning of the Private Securities Litigation Act of 1995. When used in this current report, the words or phrases "will", "will likely result," "expected to," "will continue," "anticipated," "estimate," "projected," "intend," "goal," or similar expressions are intended to identify "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are subject to certain risks, known and unknown, and uncertainties, many of which are beyond the control of the Company. Such uncertainties and risks include, but are not limited to, our ability to successfully execute our growth strategy, changes in laws or regulations, economic conditions, dependence on management, dilution to stockholders, lack of capital, the effects of rapid growth upon the Company and the ability of management to effectively respond to the growth and demand for products and services of the Company, newly developing technologies, the Company's ability to compete, conflicts of interest in related party transactions, regulatory matters, protection of technology, lack of industry standards, the effects of competition and the ability of the Company to obtain future financing. An extensive list of factors that can affect future results are discussed in the Company's Annual Report on form 10-K for the year ended June 30, 2023 and its Quarterly Reports on Form 10-Q for the periods ended September 30, 2023, December 31, 2023, and March 31, 2024 under the heading "Risk Factors" in Item IA thereof, and other documents filed from time to time with the Securities and Exchange Commission. Such factors could materially adversely affect the Company's financial performance and could cause the Company's actual results for future periods to differ materially from any opinions or statements expressed within this current repo
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. UPEXI, INC. Dated: November 22, 2024 /s/ Andrew J. Norstrud Name: Andrew J. Norstrud Title: Chief Financial Officer 3